Table 1.
Baseline characteristics of included patients (n = 52).
| Total | % | Low MMB | % | High MMB | % | P value | ||
|---|---|---|---|---|---|---|---|---|
| Age | < 65 | 32 | 61.5% | 19 | 63.3% | 11 | 36.7% | 0.100 |
| ≥ 65 | 20 | 38.5% | 7 | 38.9% | 11 | 61.1% | ||
| Gender | Male | 35 | 67.3% | 15 | 46.9% | 17 | 53.1% | 0.838 |
| Female | 17 | 32.7% | 7 | 43.8% | 9 | 56.3% | ||
| ECOG PS | 0 | 18 | 34.6% | 9 | 52.9% | 8 | 47.1% | 0.464 |
| 1 | 34 | 65.4% | 13 | 41.9% | 18 | 58.1% | ||
| Histology | Adenocarcinoma | 26 | 50.0% | 13 | 56.5% | 10 | 43.5% | 0.252* |
| Squamous | 14 | 26.9% | 6 | 42.9% | 8 | 57.1% | ||
| Adenosquamous | 2 | 3.8% | 1 | 50.0% | 1 | 50.0% | ||
| Large cell carcinoma | 1 | 1.9% | 0 | 0.0% | 1 | 100.0% | ||
| NOS | 9 | 17.3% | 3 | 37.5% | 5 | 62.5% | ||
| Regimen | Docetaxel + cisplatin | 35 | 67.3% | 18 | 54.5% | 15 | 45.5% | 0.938 |
| Docetaxel + carboplatin | 17 | 32.7% | 8 | 53.3% | 7 | 46.7% | ||
| Mecapegfilgrastim | Yes | 33 | 63.5% | 20 | 76.9% | 18 | 81.8% | 0.953 |
| No | 19 | 36.5% | 6 | 23.1% | 4 | 18.2% | ||
| Response rate | CR | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | |
| PR | 11 | 21.2% | 8 | 80.0% | 2 | 20.0% | 0.249 | |
| SD | 29 | 55.8% | 15 | 55.6% | 12 | 44.4% | ||
| PD | 12 | 23.1% | 1 | 9.1% | 10 | 90.9% |
ECOG PS: Eastern Cooperative Oncology Group performance status; NOS: not otherwise specified; CR: complete response; PR: partial response; SD: stable disease; PD: progression disease; MMB, molecular mutational burden.
*, p value refers to adenocarcinoma vs. non-adenocarcinoma.
**, 52 blood samples were collected at baseline and 48 samples had measurable concentration (4 of them were excluded due to negligible level).